Zhende went public on the Shanghai Stock Exchange on April 12, 2018 (stock abbreviation: Zhende Healthcare; stock code: 603301). The company has issued 25 million new shares this time, accounting for 25% of the outstanding shares after the issuance, at a price of RMB 19.82 per share. The lead underwriter was CITIC Securities Co., Ltd.
Founded in 1994, Zhende specializes in the production, R & D and sales of medical dressings. The company’s product portfolio consists of modern wound dressings, infection control in operating rooms, traditional wound care and pressure therapy and immobilization. The company has evolved into one of the most influential medical dressing manufacturers in China with an extensive product range and a large business scale.
Zhende has built a marketing network that covers the major markets worldwide and has delivered high-quality products and premium services that are recognized by Chinese and overseas customers. The company has established an efficient partnership with a number of internationally renowned medical device manufacturers, and has sold its products to many countries and regions in Europe, North America, Asia, South America, Africa and Oceania. In the Chinese market, the company has established a stable marketing network with its products sold in many medical institutions and pharmacy chains and customers in most provinces and cities across the country.
On the basis of the existing product line, Zhende has actively deployed new products in the fields of cleaning and disinfection, stoma care, sports rehabilitation and so on. Through a complete product portfolio, the company provides customers with one-stop solutions to wound care, infection control in operating room, pressure therapy and immobilization.